Last reviewed · How we verify
Ophthalmic Insert
An ophthalmic insert that delivers medication directly to the eye to treat ocular surface disease and inflammation.
An ophthalmic insert that delivers medication directly to the eye to treat ocular surface disease and inflammation. Used for Dry eye disease, Ocular surface disease.
At a glance
| Generic name | Ophthalmic Insert |
|---|---|
| Also known as | OTX-TP |
| Sponsor | Ocular Therapeutix, Inc. |
| Drug class | Ophthalmic insert / sustained-release device |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Ocular Therapeutix develops sustained-release ophthalmic inserts designed to provide prolonged drug delivery to the eye. The insert formulation allows for controlled release of active pharmaceutical ingredients over an extended period, reducing the need for frequent topical dosing while maintaining therapeutic concentrations at the ocular surface.
Approved indications
- Dry eye disease
- Ocular surface disease
Common side effects
- Ocular irritation
- Foreign body sensation
- Conjunctival hyperemia
Key clinical trials
- Influence of Tamponade on Retinal Shift in Eyes Undergoing Vitrectomy for Rhegmatogenous Retinal Detachment: A Comparison of Gas Versus Silicone Oil in a Pakistani Population (NA)
- Location- and Frequency-Dependent Effects of Thalamic Temporal Interference Stimulation During Sleep (NA)
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- Ocular Hypotony and Refractive Predictability in RRD Surgery (NA)
- Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 (NA)
- External Ventricular Drain Placement Stealth Study (NA)
- Virtual Reality Versus Computer-Based Simulation in Electrocardiogram Education (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ophthalmic Insert CI brief — competitive landscape report
- Ophthalmic Insert updates RSS · CI watch RSS
- Ocular Therapeutix, Inc. portfolio CI